Antibiotic adjuvants: Multicomponent anti-infective strategies

Expert Reviews in Molecular Medicine

Volumn 13, Issue , 2011, Pages

  Kalan, Lindsay ^a   Wright, Gerard D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BACITRACIN; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; CYCLOSERINE; DICLOFENAC; GENTAMICIN; ISONIAZID; OXACILLIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; STREPTOMYCIN; SULTAMICILLIN; TEICOPLANIN; TIMENTIN; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BIOFILM; COMBINATION CHEMOTHERAPY; DRUG POTENCY; DRUG POTENTIATION; ENTEROCOCCUS; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TUBERCULOSIS; BACTERIAL INFECTION; DRUG DEVELOPMENT; REVIEW;

BACTERIA (MICROORGANISMS); KLEBSIELLA PNEUMONIAE;

ADJUVANTS, PHARMACEUTIC; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 79956079536     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399410001766     Document Type: Article

References (104)

1. Livermore, D.M. (2009) Has the era of untreatable infections arived? Journal of Antimicrobial Chemotherapy 64 (Suppl 1), i29-i36
2. Boucher, H.W. et al. (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clinical Infectious Diseases 48, 1-12
3. Arias, C.A. and Murray, B.E. (2009) Antibioticresistant bugs in the 21st century - a clinical superchallenge. New England Journal of Medicine 360, 439-443
4. Spellberg, B. et al. (2008) The epidemic of antibioticresistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clinical Infectious Diseases 46, 155-164 (Pubitemid 351269151)
5. Peleg, A.Y., Seifert, H. and Paterson, D.L. (2008) Acinetobacter baumannii: emergence of a successful pathogen. Clinical Microbiology Reviews 21, 538-582
6. Zhang, Y. and Yew, W.W. (2009) Mechanisms of drug resistance in Mycobacterium tuberculosis. International Journal of Tuberculosis and Lung Disease 13, 1320-1330
7. Workowski, K.A., Berman, S.M. and Douglas, J.M., Jr (2008) Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Annals of Internal Medicine 148, 606-613 (Pubitemid 351669134)
8. Bratu, S. et al. (2005) Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrobial Agents and Chemotherapy 49, 3018-3020 (Pubitemid 40917631)
9. Kumarasamy, K.K. et al. (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infectious Diseases 10, 597-602
10. Peleg, A.Y. and Hooper, D.C. (2010) Hospitalacquired infections due to gram-negative bacteria. New England Journal of Medicine 362, 1804-1813
11. Giamarellou, H. and Poulakou, G. (2009) Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69, 1879-1901
12. Fischbach, M.A. andWalsh, C.T. (2009) Antibiotics for emerging pathogens. Science 325, 1089-1093
13. Fournier, P.E. et al. (2006) Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genetics 2, e7
14. Canton, R. (2009) Antibiotic resistance genes from the environment: a perspective through newly identified antibiotic resistance mechanisms in the clinical setting. Clinical Microbiology and Infection 15 (Suppl 1), 20-25
15. Wright, G.D. (2010) Antibiotic resistance in the environment: a link to the clinic? Current Opinion in Microbiology 13, 589-594
16. Payne, D.J. et al. (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery.Nature Reviews. Drug Discovery 6, 29-40 (Pubitemid 46020284)
17. Hamad, B. (2010) The antibiotics market. Nature Reviews. Drug Discovery 9, 675-676
18. Shafer, R.W. and Vuitton, D.A. (1999) Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomedicine and Pharmacotherapy 53, 73-86 (Pubitemid 29356458)
19. Pillai, S.K., Moellering, R.C. and Eliopoulos, G.M. (2005) Antimicrobial combinations (5th edn) (Lorian V., series ed.), Williams and Wilkins, Baltimore
20. Pillai S., Moellering R.C., Eliopoulos G.M.(2005). Antimicrobial combinations. In Antibiotics in Laboratory Medicine 5th edn Lorian V. ed. Lippincott Williams & Wilkins Philadelphia.
21. Pillai, S., Moellering, R.C. and Eliopoulos, G.M. (2005) Antimicrobial combinations. In Antibiotics in Laboratory Medicine (5th edn) Lorian V., ed.), Lippincott Williams & Wilkins, Philadelphia 21 Holm, S.E. (1986) Interaction between beta-lactam and other antibiotics. Reviews of Infectious Diseases 8 (Suppl 3), S305-S314
22. Reeves, D.S. (1971) Sulphamethoxazoletrimethoprim: the first two years. Journal of Clinical Pathology 24, 430-437
23. GSK (2008) PR SEPTRA injection product monograph. [www.gsk.ca/english/ docs-pdf/ Septra-PM-20081127-EN.pdf]
24. Burchall, J.J. and Hitchings, G.H. (1965) Inhibitor binding analysis of dihydrofolate reductases from various species. Molecular Pharmacology 1, 126-136
25. Li, R., Hansch, C. and Kaufman, B.T. (1982) A comparison of the inhibitory action of 5- (substituted-benzyl)-2,4-diaminopyrimidines on dihydrofolate reductase from chicken liver with that from bovine liver. Journal of Medicinal Chemistry 25, 435-440 (Pubitemid 12078649)
26. Kwon,Y.K. et al. (2008)Adomino effect in antifolate drug action in Escherichia coli. Nature Chemical Biology 4, 602-608
27. Moellering, R.C., Jr and Weinberg, A.N. (1971) Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14Clabeled streptomycin by enterococci. Journal of Clinical Investigation 50, 2580-2584
28. Moellering, R.C., Jr Wennersten, C. and Weinberg, A.N. (1971) Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. Journal of Laboratory and Clinical Medicine 77, 821-828
29. Barnes, A.I., Herrero, I.L. and Albesa, I. (2005) New aspect of the synergistic antibacterial action of ampicillin and gentamicin. International Journal of Antimicrobial Agents 26, 146-151 (Pubitemid 41021967)
30. Chanbusarakum, P. and Murray, P.R. (1978) Analysis of the interactions between piperacillin, ticarcillin, or carbenicillin and aminoglycoside antibiotics. Antimicrobial Agents and Chemotherapy 14, 505-506 (Pubitemid 9025679)
31. Moellering, R.C., Jr Eliopoulos, G.M. and Allan, J.D. (1986) Beta-lactam/aminoglycoside combinations: interactions and their mechanisms. American Journal of Medicine 80, 30-34 (Pubitemid 16090512)
32. Russell, E.J. and Sutherland, R. (1975) Activity of amoxycillin against enterococci and synergism with aminoglycoside antibiotics. Journal of Medical Microbiology 8, 1-10
33. Noone, P. and Pattison, J.R. (1971) Therapeutic implications of interaction of gentamicin and penicillins. Lancet 2, 575-578
34. Waitz, J.A. et al. (1972) Biological aspects of the interaction between gentamicin and carbenicillin. Journal of Antibiotics 25, 219-225
35. Chan, D.I. and Vogel, H.J. (2010) Current understanding of fatty acid biosynthesis and the acyl carrier protein. Biochemical Journal 430, 1-19
36. Campbell, E.A. et al. (2001) Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 104, 901-912 (Pubitemid 32289282)
37. Cegielski, J.P. (2010) Extensively drug-resistant tuberculosis: there must be some kind of way out of here. Clinical Infectious Diseases 50 (Suppl 3), S195-200
38. Shah, N.S. et al. (2007) Extensively drug-resistant tuberculosis - United States, 1993-2006. MMWR, Morbidityand MortalityWeekly Report 56, 250-253
39. Hugonnet, J.E. et al. (2009) Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323, 1215-1218
40. Bugg, T.D.H. et al. (1991) Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30, 10408-10415
41. Perichon, B. and Courvalin, P. (2006) Synergism between beta-lactams and glycopeptides against VanA-type methicillin-resistant Staphylococcus aureus and heterologous expression of the vanA operon. Antimicrobial Agents and Chemotherapy 50, 3622-3630 (Pubitemid 44684873)
42. Kobayashi, Y. (2005) Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. Journal of Infection and Chemotherapy 11, 259-261 (Pubitemid 41570025)
43. De Pascale, G. and Wright, G.D. (2010) Antibiotic resistance by enzyme inactivation: from mechanisms to solutions. Chembiochem 11, 1325-1334
44. Brown, A.G. et al. (1976) Naturally-occurring betalactamase inhibitors with antibacterial activity. Journal of Antibiotics 29, 668-669
45. Fisher, J.F., Meroueh, S.O. and Mobashery, S. (2005) Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chemical Reviews 105, 395-424 (Pubitemid 40351628)
46. Drawz, S.M. and Bonomo, R.A. (2010) Three decades of beta-lactamase inhibitors. Clinical Microbiology Reviews 23, 160-201
47. Boehr, D.D. et al. (2003) Broad-spectrum peptide inhibitors of aminoglycoside antibiotic resistance enzymes. Chemistry and Biology 10, 189-196 (Pubitemid 36250977)
48. Daigle, D.M., McKay, G.A. andWright, G.D. (1997) Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors. Journal of Biological Chemistry 272, 24755-24758 (Pubitemid 27415642)
49. Allen, N.E. et al. (1982) 7-Hydroxytropolone: an inhibitor of aminoglycoside-2″-Oadenylyltransferase. Antimicrobial Agents and Chemotherapy 22, 824-831
50. Clancy, J. et al. (1995) Assays to detect and characterize synthetic agents that inhibit the ErmC methyltransferase. Journal of Antibiotics 48, 1273-1279
51. Feder, M. et al. (2008) Virtual screening and experimental verification to identify potential inhibitors of the ErmC methyltransferase responsible for bacterial resistance against macrolide antibiotics. ChemMedChem 3, 316-322
52. Hajduk, P.J. et al. (1999) Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis. Journal of Medicinal Chemistry 42, 3852-3859 (Pubitemid 29453466)
53. D'Costa, V.M. et al. (2006) Sampling the antibiotic resistome. Science 311, 374-377
54. Li, J. et al. (2006) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infectious Diseases 6, 589-601
55. Lee, J.H. et al. (2009) New disturbing trend in antimicrobial resistance of gram-negative pathogens. PLoS Pathogens 5, e1000221
56. Aoki, N. et al. (2009) Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 63, 534-542
57. Gordon, N.C., Png, K. and Wareham, D.W. (2010) Potent synergy and sustained bactericidal activity of a vancomycin/colistin combination versus multi-drug resistant strains of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 54, 5316-22
58. Moffatt, J.H. et al. (2010) Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide. Antimicrobial Agents and Chemotherapy 54, 4971-7
59. Velkov, T. et al. (2010) Structure - activity relationships of polymyxin antibiotics. Journal of Medicinal Chemistry 53, 1898-1916
60. De Leon, G.P. et al. (2006) An in vitro screen of bacterial lipopolysaccharide biosynthetic enzymes identifies an inhibitor of ADP-heptose biosynthesis. Chemistry and Biology 13, 437-441
61. Desroy, N. et al. (2009) Towards Gram-negative antivirulence drugs: new inhibitors of HldE kinase. Bioorganic and Medicinal Chemistry 17, 1276-1289
62. Poole, K. et al. (1993) Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. Journal of Bacteriology 175, 7363-7372 (Pubitemid 23339316)
63. Poole, K. and Srikumar, R. (2001) Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Current Topics in Medicinal Chemistry 1, 59-71
64. Piddock, L.J. (2006) Multidrug-resistance efflux pumps - not just for resistance. Nature Reviews. Microbiology 4, 629-636 (Pubitemid 44317025)
65. Pages, J.M. and Amaral, L. (2009) Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochimica et Biophysica Acta 1794, 826-833
66. Pages, J.M., Masi, M. and Barbe, J. (2005) Inhibitors of efflux pumps in Gram-negative bacteria. Trends in Molecular Medicine 11, 382-389 (Pubitemid 41080580)
67. Markham, P.N. et al. (1999) Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 43, 2404-2408 (Pubitemid 29471218)
68. Neyfakh, A.A., Borsch, C.M. and Kaatz,G.W. (1993) Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrobial Agents and Chemotherapy 37, 128-129 (Pubitemid 23019184)
69. Mahamoud, A. et al. (2007) Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. Journal of Antimicrobial Chemotherapy 59, 1223-1229 (Pubitemid 47073340)
70. Thorarensen, A. et al. (2001) 3-Arylpiperidines as potentiators of existing antibacterial agents. Bioorganic and Medicinal Chemistry Letters 11, 1903-1906 (Pubitemid 32675314)
71. Piddock, L.J. et al. (2010) Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in Gram-negative bacteria. Journal of Antimicrobial Chemotherapy 65, 1215-1223
72. Stermitz, F.R. et al. (2000) Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5''-methoxyhydnocarpin, a multidrug pump inhibitor. Proceedings of the National Academy of Sciences of theUnitedStates ofAmerica 97, 1433-1437 (Pubitemid 30118458)
73. Stermitz, F.R. et al. (2002) Two flavonols from Artemisa annua which potentiate the activity of berberine and norfloxacin against a resistant strain of Staphylococcus aureus. Planta Medica 68, 1140-1141 (Pubitemid 36140326)
74. Morel, C. et al. (2003) Isoflavones as potentiators of antibacterial activity. Journal of Agricultural and Food Chemistry 51, 5677-5679
75. Stavri, M., Piddock, L.J. and Gibbons, S. (2007) Bacterial efflux pump inhibitors from natural sources. Journal of Antimicrobial Chemotherapy 59, 1247-1260 (Pubitemid 47073343)
76. Chusri, S. et al. (2009) Enhancing antibiotic activity: a strategy to control Acinetobacter infections. Journal of Antimicrobial Chemotherapy 64, 1203-1211
77. Flemming, H.C. and Wingender, J. (2010) The biofilm matrix. Nature Reviews. Microbiology 8, 623-633
78. Mulcahy, H., Charron-Mazenod, L. and Lewenza, S. (2008) Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms. PLoS Pathogens 4, e1000213
79. Hatch, R.A. and Schiller, N.L. (1998) Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 42, 974-977 (Pubitemid 28216397)
80. Shigeta, M. et al. (1997) Permeation of antimicrobial agents through Pseudomonas aeruginosa biofilms: a simple method. Chemotherapy 43, 340-345 (Pubitemid 27346061)
81. Rodriguez-Martinez, J.M., Ballesta, S. and Pascual, A. (2007) Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and cotrimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms. International Journal of Antimicrobial Agents 30, 366-368 (Pubitemid 47364777)
82. Walters, M.C., III et al. (2003) Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrobial Agents and Chemotherapy 47, 317-323 (Pubitemid 36070381)
83. Spoering, A.L. and Lewis, K. (2001) Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. Journal of Bacteriology 183, 6746-6751 (Pubitemid 33064186)
84. Lewis, K. (2007) Persister cells, dormancy and infectious disease. Nature Reviews. Microbiology 5, 48-56 (Pubitemid 44942303)
85. Dorr, T., Vulic, M. and Lewis, K. (2010) Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biology 8, e1000317
86. Correia, F.F. et al. (2006) Kinase activity of overexpressed HipA is required for growth arrest and multidrug tolerance in Escherichia coli. Journal of Bacteriology 188, 8360-8367 (Pubitemid 44894035)
87. Richards, J.J. and Melander, C. (2009) Controlling bacterial biofilms. Chembiochem 10, 2287-2294
88. Kolodkin-Gal, I. et al. (2010) D-amino acids trigger biofilm disassembly. Science 328, 627-629
89. Junker, L.M. and Clardy, J. (2007) High-throughput screens for small-molecule inhibitors of Pseudomonas aeruginosa biofilm development. Antimicrobial Agents and Chemotherapy 51, 3582-3590 (Pubitemid 47519347)
90. Rogers, S.A. and Melander, C. (2008) Construction and screening of a 2-aminoimidazole library identifies a small molecule capable of inhibiting and dispersing bacterial biofilms across order, class, and phylum. Angewandte Chemie (International Edition in English) 47, 5229-5231
91. Huigens, R.W., III et al. (2007) Inhibition of Pseudomonas aeruginosa biofilm formation with Bromoageliferin analogues. Journal of American Chemical Society 129, 6966-6967
92. Richards, J.J. et al. (2008) Synthesis and screening of an oroidin library against Pseudomonas aeruginosa biofilms. Chembiochem 9, 1267-1279
93. Rogers, S.A. et al. (2010) Synergistic effects between conventional antibiotics and 2-aminoimidazolederived antibiofilm agents. Antimicrobial Agents and Chemotherapy 54, 2112-2118
94. Mazumdar, K., Asok Kumar, K. and Dutta, N.K. (2010) Potential role of the cardiovascular nonantibiotic (helper compound) amlodipine in the treatment of microbial infections: scope and hope for the future. International Journal of Antimicrobial Agents 36, 295-302
95. Dasgupta, A. et al. (2010) Experimental analyses of synergistic combinations of antibiotics with a recently recognised antibacterial agent, lacidipine. European Journal of Clinical Microbiology and Infectious Diseases 29, 239-243
96. Fukuda, T. et al. (2005) Phenatic acids A and B, new potentiators of antifungal miconazole activity produced by Streptomyces sp. K03-0132. Journal of Antibiotics 58, 252-259 (Pubitemid 40740600)
97. Sun, L. et al. (2009) In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans. Antimicrobial Agents and Chemotherapy 53, 1586-1591
98. Yamazaki, H. et al. (2009) Xanthoradones, new potentiators of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Penicillium radicum FKI-3765-2: I. Taxonomy, fermentation, isolation and biological properties. Journal of Antibiotics 62, 431-434
99. Yamazaki, H., Omura, S. and Tomoda, H. (2010) Xanthoradone C, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Penicillium radicum FKI-3765-2. Journal of Antibiotics 63, 329-330
100. Dutta, N.K. et al. (2007) Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice. International Journal of Antimicrobial Agents 30, 336-340 (Pubitemid 47371086)
101. Mazumdar, K. et al. (2009) The anti-inflammatory non-antibiotic helper compound diclofenac: an antibacterial drug target. European Journal of Clinical Microbiology and Infectious Diseases 28, 881-891
102. Fukuda, T., Tomoda, H. and Omura, S. (2005) Citridones, new potentiators of antifungal miconazole activity, produced by Penicillium sp. FKI-1938. II. Structure elucidation. Journal of Antibiotics 58, 315-321 (Pubitemid 40874449)
103. Fukuda, T. et al. (2005) Citridones, new potentiators of antifungal miconazole activity, produced by Penicillium sp. FKI-1938. I. Taxonomy, fermentation, isolation and biological properties. Journal of Antibiotics 58, 309-314 (Pubitemid 40874448)
104. Torella, J.P., Chait, R. and Kishony, R. (2010) Optimal drug synergy in antimicrobial treatments. PLoS Computational Biology 6, e1000796